Lamotrigine - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for lamotrigine and what is the scope of patent protection?

Lamotrigine is the generic ingredient in five branded drugs marketed by Glaxosmithkline Llc, Actavis Elizabeth, Alembic, Amneal Pharms, Dr Reddys Labs Ltd, Endo Operations, Rubicon, Torrent, Wockhardt Bio Ag, Yiling, Zydus Pharms, Aurobindo Pharma, Glenmark Pharms Ltd, Jubilant Generics, Norvium Bioscience, Sandoz, Taro, Teva, Watson Labs, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Amring Pharms, Impax Labs Inc, Sciegen Pharms Inc, Actavis Totowa, Alembic Pharms Ltd, Alkem Labs Ltd, Chartwell Molecular, Granules, Hikma Pharms, Ipca Labs, Jubilant Cadista, Lupin Ltd, Natco Pharma, Rising, Roxane, Taro Pharm Inds, Torrent Pharms, Unichem Labs Ltd, Zennova, and Zydus Pharms Usa, and is included in fifty-five NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lamotrigine has forty-four patent family members in thirty countries.

There are thirty-two drug master file entries for lamotrigine. Fifty-three suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for lamotrigine

International Patents:	44
US Patents:	1
Tradenames:	5
Applicants:	41
NDAs:	55
Drug Master File Entries:	32
Finished Product Suppliers / Packagers:	53
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	210
Patent Applications:	6,918
Drug Prices:	Drug price trends for lamotrigine
Drug Sales Revenues:	Drug sales revenues for lamotrigine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lamotrigine
What excipients (inactive ingredients) are in lamotrigine?	lamotrigine excipients list
DailyMed Link:	lamotrigine at DailyMed

See drug prices for lamotrigine

Drug Sales Revenue Trends for lamotrigine

See drug sales revenues for lamotrigine

Recent Clinical Trials for lamotrigine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mental Health Services in the Capital Region, Denmark	Phase 4
Dr. Inge Winter	Phase 4
Westfälische Wilhelms-Universität Münster	Phase 4

See all lamotrigine clinical trials

Generic filers with tentative approvals for LAMOTRIGINE

Applicant	Application No.	Strength	Dosage Form
⤷ Subscribe	⤷ Subscribe	200MG	TABLET;ORAL
⤷ Subscribe	⤷ Subscribe	150MG	TABLET;ORAL
⤷ Subscribe	⤷ Subscribe	100MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for lamotrigine

Drug Class	Anti-epileptic Agent Mood Stabilizer
Mechanism of Action	Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Anatomical Therapeutic Chemical (ATC) Classes for lamotrigine

N03AX	Other antiepileptics
N03A	ANTIEPILEPTICS
N03	ANTIEPILEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for LAMOTRIGINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LAMICTAL XR	Extended-release Tablets	lamotrigine	25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg	022115	1	2014-02-12
LAMICTAL ODT	Orally Disintegrating Tablets	lamotrigine	25 mg, 50 mg, 100 mg, and 200 mg	022251	1	2009-12-21

US Patents and Regulatory Information for lamotrigine

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	LAMOTRIGINE	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	207763-004	Apr 1, 2020	AB	RX	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Zydus Pharms	LAMOTRIGINE	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	207763-001	Apr 1, 2020	AB	RX	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Hikma Pharms	LAMOTRIGINE	lamotrigine	TABLET;ORAL	078134-003	Apr 19, 2011		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-004	Dec 27, 1994		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Sciegen Pharms Inc	LAMOTRIGINE	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	206382-004	Jun 17, 2016	AB	RX	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for lamotrigine

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-003	Dec 27, 1994	4,602,017*PED	⤷ Subscribe
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-001	Dec 27, 1994	4,602,017*PED	⤷ Subscribe
Glaxosmithkline Llc	LAMICTAL CD	lamotrigine	TABLET, FOR SUSPENSION;ORAL	020764-004	Sep 8, 2000	4,602,017*PED	⤷ Subscribe
Glaxosmithkline Llc	LAMICTAL	lamotrigine	TABLET;ORAL	020241-005	Dec 27, 1994	4,602,017*PED	⤷ Subscribe
Glaxosmithkline Llc	LAMICTAL CD	lamotrigine	TABLET, FOR SUSPENSION;ORAL	020764-002	Aug 24, 1998	5,698,226*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for lamotrigine

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Colombia	5680405	FORMULACION DE LAMOTRIGINA DE LIBERACION PROLONGADA Y USO DE LA MISMA PARA SU PREPARACION	⤷ Subscribe
Germany	60326590		⤷ Subscribe
Israel	166424	SUSTAINED RELEASE FORMULATIONS COMPRISING LAMOTRIGINE AND AN OUTER COATING WITH ONE OR MORE ORIFICES	⤷ Subscribe
Iceland	2681		⤷ Subscribe
Russian Federation	2007143372	КОМПОЗИЦИИ С ПРОЛОНГИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, ВКЛЮЧАЮЩИЕ ЛАМОТРИГИН	⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.